Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction

[1]  C. Christoffersen,et al.  Apolipoprotein M and risk of type 2 diabetes. , 2020, The Journal of clinical endocrinology and metabolism.

[2]  J. Lamb,et al.  Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes , 2020, Diabetes.

[3]  D. Rader,et al.  Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure , 2020, Circulation.

[4]  K. Dickstein,et al.  Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. , 2020, JACC. Heart failure.

[5]  Zhuyin Li,et al.  Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. , 2020, JACC. Heart failure.

[6]  C. Yancy,et al.  Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[7]  A. Scheen.  Cardiovascular Effects of New Oral Glucose-Lowering Agents , 2018, Circulation research.

[8]  Shannon M. Dunlay,et al.  Epidemiology of heart failure with preserved ejection fraction , 2017, Nature Reviews Cardiology.

[9]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[10]  B. Lindman.  The Diabetic Heart Failure With Preserved Ejection Fraction Phenotype: Is it Real and Is It Worth Targeting Therapeutically? , 2017, Circulation.

[11]  Deepak L. Bhatt,et al.  Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. , 2016, American heart journal.

[12]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[13]  Angelo Avogaro,et al.  Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. , 2015, JACC. Heart failure.

[14]  Robert J Mentz,et al.  Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[15]  B. Borlaug,et al.  The pathophysiology of heart failure with preserved ejection fraction , 2014, Nature Reviews Cardiology.

[16]  B. French,et al.  Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes , 2014, Circulation.

[17]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[18]  Tyler J VanderWeele,et al.  A three-way decomposition of a total effect into direct, indirect, and interactive effects. , 2013, Epidemiology.

[19]  Rachel Ostroff,et al.  Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery , 2010, PLoS ONE.

[20]  Q. Wang,et al.  Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. , 2010, Biochimica et biophysica acta.

[21]  B. Levkau,et al.  Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. , 2008, Cardiovascular research.

[22]  B. Porse,et al.  Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice* , 2008, Journal of Biological Chemistry.

[23]  Melanie Hilario,et al.  Approaches to dimensionality reduction in proteomic biomarker studies , 2007, Briefings Bioinform..

[24]  P. Nilsson-ehle,et al.  Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. , 2007, Biochimica et biophysica acta.

[25]  H. Zou.  The Adaptive Lasso and Its Oracle Properties , 2006 .

[26]  P. Nilsson-ehle,et al.  Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. , 2006, Biochemical and biophysical research communications.

[27]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[28]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[29]  D. Cox,et al.  An Analysis of Transformations , 1964 .